A histopathological study of the effects of 6-month versus 12-month interferon alpha-2b therapy in chronic hepatitis C

被引:27
作者
Ziol, M
VanNhieu, JT
RoudotThoraval, F
Metreau, JM
Deugnier, Y
Dhumeaux, D
Zafrani, ES
机构
[1] HOP HENRI MONDOR, SERV ANAT & CYTOL PATHOL, F-94010 CRETEIL, FRANCE
[2] HOP HENRI MONDOR, SERV HEPATOL, F-94010 CRETEIL, FRANCE
关键词
chronic hepatitis C; fibrosis; hepatitis C virus; histological score; interferon alpha therapy;
D O I
10.1016/S0168-8278(96)80286-8
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Interferon therapy has been shown to have beneficial effects in chronic hepatitis C, but the optimal duration of treatment has not been clearly defined, The aims of this study were: (a) to perform a detailed histological comparison of the effects of a 6-month and a 12-month treatment using the Knodell score as well as a recently proposed grid of analysis, (b) to determine possible histological predictive factors of response to therapy, and (c) to attempt to relate histological and biochemical modifications, Methods: Liver biopsies obtained before and 18 months after beginning of treatment were therefore compared in 26 patients treated for 6 months, and in 34 patients treated for 12 months, Results: Six months of treatment induced a significant decrease in periportal (p=0.02) and intralobular (p=0.004) hepatocyte necrosis, The same items were improved in the 12-month-treated patients but, in addition, portal inflammation (p=0.01), bile duct lesions (p=0.03), lymphoid aggregates (p=0.002) and fibrosis (p=0.008) were also improved, according to the Knodell score, Low scores for fibrosis, steatosis and cholangiolar proliferation on the pretreatment liver biopsy could be considered predictive factors for alanine aminotransferase normalization at 6 months, There was no relationship between biochemical response and modification of fibrosis. Conclusion: Our results suggest that: (a) a decrease in fibrosis might be detected only after a 12-month interferon treatment, and (b) initial fibrosis, cholangiolar proliferation and steatosis are predictive of a lack of biochemical response, The absence of a relation between biochemical response and evolution of fibrosis implies that the evaluation of treatments in chronic hepatitis C should always include a detailed histopathological study.
引用
收藏
页码:833 / 841
页数:9
相关论文
共 31 条
[1]   THE HISTOLOGICAL FEATURES OF CHRONIC HEPATITIS-C AND AUTOIMMUNE CHRONIC HEPATITIS - A COMPARATIVE-ANALYSIS [J].
BACH, N ;
THUNG, SN ;
SCHAFFNER, F .
HEPATOLOGY, 1992, 15 (04) :572-577
[2]  
BEDOSSA P, 1994, HEPATOLOGY, V20, P15
[3]   RANDOMIZED TRIAL OF LYMPHOBLASTOID ALPHA-INTERFERON IN CHRONIC HEPATITIS-C - EFFECTS ON INFLAMMATION, FIBROGENESIS AND VIREMIA [J].
CAMPS, J ;
CASTILLA, A ;
RUIZ, J ;
CIVEIRA, MP ;
PRIETO, J .
JOURNAL OF HEPATOLOGY, 1993, 17 (03) :390-396
[4]   TRANSFORMING GROWTH FACTOR-BETA-1 AND FACTOR-ALPHA IN CHRONIC LIVER-DISEASE - EFFECTS OF INTERFERON ALFA THERAPY [J].
CASTILLA, A ;
PRIETO, J ;
FAUSTO, N .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (14) :933-940
[5]   COMPARISON OF 1 OR 3 MU OF INTERFERON ALFA-2B AND PLACEBO IN PATIENTS WITH CHRONIC NON-A, NON-B HEPATITIS [J].
CAUSSE, X ;
GODINOT, H ;
CHEVALLIER, M ;
CHOSSEGROS, P ;
ZOULIM, F ;
OUZAN, D ;
HEYRAUD, JP ;
FONTANGES, T ;
ALBRECHT, J ;
MESCHIEVITZ, C ;
TREPO, C .
GASTROENTEROLOGY, 1991, 101 (02) :497-502
[6]  
Chemello L., 1993, Journal of Hepatology, V18, pS10
[7]   SENSITIVITY, SPECIFICITY, AND PREDICTABILITY OF BIOPSY INTERPRETATIONS IN CHRONIC HEPATITIS [J].
CZAJA, AJ ;
CARPENTER, HA .
GASTROENTEROLOGY, 1993, 105 (06) :1824-1832
[8]   HISTOLOGIC-CHANGES IN LIVER-BIOPSY SPECIMENS PRODUCED BY RECOMBINANT INTERFERON-ALPHA-2B THERAPY FOR CHRONIC NON-A, NON-B VIRAL-HEPATITIS - A RANDOMIZED CONTROLLED TRIAL [J].
DAVID, E ;
PUCCI, A ;
PALLADIN, D ;
SARACCO, G ;
GARELLO, E ;
PINTUS, C ;
ROCCA, G ;
CHIANDUSSI, L ;
SOLINAS, A ;
MOLLO, F ;
RIZZETTO, M ;
MAZZUCCO, G ;
VERME, G .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1992, 98 (04) :397-401
[9]   TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL [J].
DAVIS, GL ;
BALART, LA ;
SCHIFF, ER ;
LINDSAY, K ;
BODENHEIMER, HC ;
PERRILLO, RP ;
CAREY, W ;
JACOBSON, IM ;
PAYNE, J ;
DIENSTAG, JL ;
VANTHIEL, DH ;
TAMBURRO, C ;
LEFKOWITCH, J ;
ALBRECHT, J ;
MESCHIEVITZ, C ;
ORTEGO, TJ ;
GIBAS, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1501-1506
[10]   RECOMBINANT INTERFERON-ALFA THERAPY FOR CHRONIC HEPATITIS-C - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DIBISCEGLIE, AM ;
MARTIN, P ;
KASSIANIDES, C ;
LISKERMELMAN, M ;
MURRAY, L ;
WAGGONER, J ;
GOODMAN, Z ;
BANKS, SM ;
HOOFNAGLE, JH .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1506-1510